Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report

Pramod, Kumar; Pradeep, Krishna; Maidur, Rohit N.; Naveen, Chandrashekhar; Suresh, Raghavaiah

dc.contributor.author	Pramod, Kumar
dc.contributor.author	Pradeep, Krishna
dc.contributor.author	Maidur, Rohit N.
dc.contributor.author	Naveen, Chandrashekhar
dc.contributor.author	Suresh, Raghavaiah
dc.date.accessioned	2025-06-25T10:25:11Z
dc.date.available	2025-06-25T10:25:11Z
dc.date.issued	2025-03
dc.identifier.citation	Journal of Liver Cancer. 2025 March; 25(1): 134-137.	en_US
dc.identifier.issn	2288-8128
dc.identifier.uri	http://dspace.sdmucmsh.edu.in:8080/xmlui/handle/123456789/2494
dc.language.iso	en	en_US
dc.publisher	Korean Liver Cancer Association	en_US
dc.subject	Liver cirrhosis	en_US
dc.subject	Carcinoma, hepatocellular	en_US
dc.subject	Immunotherapy	en_US
dc.subject	Liver transplantation	en_US
dc.subject	Hepatitis C	en_US
dc.title	Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report	en_US
dc.type	Article	en_US